Trust Point’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.07M Buy
3,518
+522
+17% +$616K 0.3% 42
2026
Q2
$3.59M Buy
2,996
+264
+10% +$270K 0.31% 43
2026
Q1
$2.51M Buy
2,732
+18
+0.7% +$18.2K 0.22% 53
2025
Q4
$2.92M Buy
2,714
+56
+2% +$53.5K 0.23% 45
2025
Q3
$2.03M Sell
2,658
-818
-24% -$609K 0.16% 63
2025
Q2
$2.71M Buy
3,476
+621
+22% +$483K 0.26% 46
2025
Q1
$2.36M Sell
2,855
-1,165
-29% -$969K 0.22% 52
2024
Q4
$3.1M Sell
4,020
-30
-0.7% -$24.8K 0.22% 46
2024
Q3
$3.59M Buy
4,050
+290
+8% +$261K 0.27% 38
2024
Q2
$3.4M Buy
3,760
+24
+0.6% +$19.2K 0.27% 38
2024
Q1
$2.91M Buy
3,736
+52
+1% +$37K 0.23% 49
2023
Q4
$2.15M Buy
+3,684
New +$2.15M 0.18% 63

Other funds holding LLY

Trust Point's LLY Position: Q3 2026 in Review

Trust Point increased its Eli Lilly (LLY) stake by 17% in Q3 2026, buying an estimated $616K and bringing the position to 3,518 shares worth $4.07M. The position accounts for 0.3% of the portfolio, ranked #42.

Trust Point first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Trust Point held 3,518 shares of Eli Lilly worth $4.07M as of Q3 2026.
  • Trust Point bought 522 Eli Lilly shares in Q3 2026, an estimated $616K.
  • Eli Lilly made up 0.3% of Trust Point's portfolio in Q3 2026, its #42 holding.
  • Trust Point first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.